Monopar Therapeutics Inc has a consensus price target of $13, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Maxim Group on June 1, 2023, May 15, 2023, and March 29, 2023. With an average price target of $6.33 between HC Wainwright & Co., HC Wainwright & Co., and Maxim Group, there's an implied 819.21% upside for Monopar Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
06/01/2023 | MNPR | Buy Now | Monopar Therapeutics | $0.69 | 2367.34% | HC Wainwright & Co. | Sean Lee | → $17 | Reiterates | → Buy | Get Alert |
05/15/2023 | MNPR | Buy Now | Monopar Therapeutics | $0.69 | 190.28% | HC Wainwright & Co. | Sean Lee | $6 → $2 | Maintains | Buy | Get Alert |
03/29/2023 | MNPR | Buy Now | Monopar Therapeutics | $0.69 | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
03/28/2023 | MNPR | Buy Now | Monopar Therapeutics | $0.69 | 2367.34% | EF Hutton | Elemer Piros | $24 → $17 | Maintains | Buy | Get Alert |
03/24/2023 | MNPR | Buy Now | Monopar Therapeutics | $0.69 | 3383.31% | EF Hutton | Elemer Piros | → $24 | Reiterates | → Buy | Get Alert |
02/15/2023 | MNPR | Buy Now | Monopar Therapeutics | $0.69 | 770.83% | HC Wainwright & Co. | Sean Lee | → $6 | Maintains | Buy | Get Alert |
02/14/2023 | MNPR | Buy Now | Monopar Therapeutics | $0.69 | 3383.31% | EF Hutton | Elemer Piros | → $24 | Reiterates | → Buy | Get Alert |
01/23/2023 | MNPR | Buy Now | Monopar Therapeutics | $0.69 | 3383.31% | EF Hutton | Elemer Piros | → $24 | Initiates | → Buy | Get Alert |
12/09/2022 | MNPR | Buy Now | Monopar Therapeutics | $0.69 | 2512.48% | Roth Capital | Kumaraguru Raja | → $18 | Reinstates | → Buy | Get Alert |
08/16/2022 | MNPR | Buy Now | Monopar Therapeutics | $0.69 | 770.83% | HC Wainwright & Co. | Sean Lee | $9 → $6 | Maintains | Buy | Get Alert |
11/01/2021 | MNPR | Buy Now | Monopar Therapeutics | $0.69 | 1206.24% | HC Wainwright & Co. | Sean Lee | — | Initiates | → Buy | Get Alert |
The latest price target for Monopar Therapeutics (NASDAQ: MNPR) was reported by HC Wainwright & Co. on June 1, 2023. The analyst firm set a price target for $17.00 expecting MNPR to rise to within 12 months (a possible 2367.34% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Monopar Therapeutics (NASDAQ: MNPR) was provided by HC Wainwright & Co., and Monopar Therapeutics reiterated their buy rating.
There is no last upgrade for Monopar Therapeutics.
The last downgrade for Monopar Therapeutics Inc happened on March 29, 2023 when Maxim Group changed their price target from N/A to N/A for Monopar Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monopar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monopar Therapeutics was filed on June 1, 2023 so you should expect the next rating to be made available sometime around June 1, 2024.
While ratings are subjective and will change, the latest Monopar Therapeutics (MNPR) rating was a reiterated with a price target of $0.00 to $17.00. The current price Monopar Therapeutics (MNPR) is trading at is $0.69, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.